@article{154942d8e56340fa97c8362270362570,
title = "Canadian Urological Association consensus guideline: Management of testicular germ cell cancer",
author = "Hamilton, {Robert J.} and Christina Canil and Shrem, {Noa Shani} and Kopika Kuhathaas and Maria Jiang and Peter Chung and Scott North and Piotr Czaykowski and Sebastien Hotte and Eric Winquist and Christian Kollmannsberger and Armen Aprikian and Denis Souli{\`e}res and Scott Tyldesley and So, {Alan I.} and Nicholas Power and Rendon, {Ricardo A.} and Martin O{\textquoteright}Malley and Lori Wood",
note = "Funding Information: Competing interests: Dr. Hamilton has been an advisory board member for Astellas, Bayer, Janssen, TerSera; and has participated in clinical trials supported by Astellas, Bayer, Janssen. Dr. Jiang has been an advisory board member for EMD Serono and Pfizer; and has received payment from Amgen, Bayer, EMD Serono, Ipsen, and Janssen Oncology. Dr. Chung has received honoraria from AbbVie, Boston Scientific, TerSera, and Verity; and has participated in clinical trials supported by CTG, ICON, Medivation, Mount Sinai Health Systems, NRG, and Princess Margaret Cancer Centre. Dr. Hotte has been an advisory board member for AAA/Novartis, Astellas, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, and Seagen; has received honoraria from Astellas, Bayer, BMS, and Janssen; and has participated in clinical trials supported by AAA/Novartis, Astellas, BMS, CCTG, Eisai, Merck, Pfizer, SeaGen, and SignalChem. Dr. Winquist has been an advisory board member for Amgen, Bayer, Eisai, Merck, and Roche; has received an unrestricted educational grant from Eiasi; and has participated in clinical trials supported by Ayala, Eisai, Merck, and Roche. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Souli{\`e}res has been an advisory board member for Adlai-Nortye, BMS, Eisai, Ipsen, Merck, and Pfizer; and has received research grants to his institution from BMS, Eisai, Ipsen, Merck, and Pfizer. Dr. Tyldesley has received honoraria from Bayer, Janssen, and TerSera (prostate cancer); and has participated in clinical trials supported by Janssen (prostate cancer). Dr. So has been an advisory board member for Abbvie, Astellas, Bayer, Janssen, Merck, and TerSera. Dr. Rendon has been an advisory board member for and received honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, TerSera, and Tolmar; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. Dr. Wood has been an advisory board member for AstraZeneca BMS, Ipsen, Merck, and Pfizer (with no financial compensation); and has participated in clinical trials supported by AstraZeneca, BMS, and Merck (compensation to institution). The remaining authors do not report any competing personal or financial interests related to this work.",
year = "2022",
month = jun,
doi = "10.5489/cuaj.7945",
language = "English",
volume = "16",
pages = "155--173",
journal = "Journal of the Canadian Urological Association",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "6",
}
